Last reviewed 2026-05-14 · How we verify

Gynomunal® gel

Derming SRL · FDA-approved active Small molecule

Gynomunal® gel is a Vaginal probiotic/microbiota restorer Small molecule drug developed by Derming SRL. It is currently FDA-approved for Vaginal dysbiosis and recurrent vaginal infections, Maintenance of healthy vaginal microbiota. Also known as: Ialuronic acid gel.

Gynomunal® gel is a topical vaginal preparation designed to restore and maintain healthy vaginal microbiota and mucosal integrity.

Gynomunal® gel is a topical vaginal preparation designed to restore and maintain healthy vaginal microbiota and mucosal integrity. Used for Vaginal dysbiosis and recurrent vaginal infections, Maintenance of healthy vaginal microbiota.

At a glance

Generic name	Gynomunal® gel
Also known as	Ialuronic acid gel
Sponsor	Derming SRL
Drug class	Vaginal probiotic/microbiota restorer
Modality	Small molecule
Therapeutic area	Gynecology
Phase	FDA-approved

Mechanism of action

The product contains beneficial microorganisms and/or prebiotics that promote the growth of lactobacilli and restore the normal vaginal flora. By reestablishing a healthy acidic environment and protective microbial barrier, it helps prevent recurrent vaginal infections and supports vaginal health. This mechanism is typical of vaginal probiotics and microbiota-restoring therapies used in gynecological care.

Approved indications

Vaginal dysbiosis and recurrent vaginal infections
Maintenance of healthy vaginal microbiota

Common side effects

Local irritation or discomfort
Allergic reaction to formulation components

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Gynomunal® gel CI brief — competitive landscape report
Gynomunal® gel updates RSS · CI watch RSS
Derming SRL portfolio CI

Frequently asked questions about Gynomunal® gel

What is Gynomunal® gel?

Gynomunal® gel is a Vaginal probiotic/microbiota restorer drug developed by Derming SRL, indicated for Vaginal dysbiosis and recurrent vaginal infections, Maintenance of healthy vaginal microbiota.

How does Gynomunal® gel work?

Gynomunal® gel is a topical vaginal preparation designed to restore and maintain healthy vaginal microbiota and mucosal integrity.

What is Gynomunal® gel used for?

Gynomunal® gel is indicated for Vaginal dysbiosis and recurrent vaginal infections, Maintenance of healthy vaginal microbiota.

Who makes Gynomunal® gel?

Gynomunal® gel is developed and marketed by Derming SRL (see full Derming SRL pipeline at /company/derming-srl).

Is Gynomunal® gel also known as anything else?

Gynomunal® gel is also known as Ialuronic acid gel.

What drug class is Gynomunal® gel in?

Gynomunal® gel belongs to the Vaginal probiotic/microbiota restorer class. See all Vaginal probiotic/microbiota restorer drugs at /class/vaginal-probiotic-microbiota-restorer.

What development phase is Gynomunal® gel in?

Gynomunal® gel is FDA-approved (marketed).

What are the side effects of Gynomunal® gel?

Common side effects of Gynomunal® gel include Local irritation or discomfort, Allergic reaction to formulation components.

Drug class: All Vaginal probiotic/microbiota restorer drugs
Manufacturer: Derming SRL — full pipeline
Therapeutic area: All drugs in Gynecology
Indication: Drugs for Vaginal dysbiosis and recurrent vaginal infections
Indication: Drugs for Maintenance of healthy vaginal microbiota
Also known as: Ialuronic acid gel

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing